Compounds > methadone
Page last updated: 2024-10-30

methadone and Hepatitis B

methadone has been researched along with Hepatitis B in 43 studies

Methadone: A synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist. It has actions and uses similar to those of MORPHINE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1082-3)
methadone : A racemate comprising equimolar amounts of dextromethadone and levomethadone. It is a opioid analgesic which is used as a painkiller and as a substitute for heroin in the treatment of heroin addiction.
6-(dimethylamino)-4,4-diphenylheptan-3-one : A ketone that is heptan-3-one substituted by a dimethylamino group at position 6 and two phenyl groups at position 4.

Hepatitis B: INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.

Research Excerpts

ExcerptRelevanceReference
"We explored the long-term immunogenicity induced by 60 μg and 20 μg hepatitis B vaccines among patients receiving methadone maintenance treatment (MMT)."9.34Long-term durability of immunogenicity induced by standard and triple-dose hepatitis B vaccine in patients receiving methadone maintenance treatment. ( Dong, S; Feng, D; Feng, Y; Gao, L; Liang, X; Shao, Z; Shi, J; Shi, S; Wang, S; Wu, L; Wu, Y; Yao, T; Zhang, Y, 2020)
"To explore whether the immunization with high-dose (60μg) hepatitis B vaccines in patients receiving methadone maintenance treatment (MMT) could yield a superior protection against hepatitis B infection than did the standard dose (20μg)."9.24Immunogenicity and safety of a high-dose hepatitis B vaccine among patients receiving methadone maintenance treatment: A randomized, double-blinded, parallel-controlled trial. ( Feng, D; Feng, Y; Gao, L; Liang, X; Shi, J; Shi, S; Wang, S; Yao, T; Zhang, Y, 2017)
"Despite the efforts to curb viral hepatitis and HIV infections through Methadone clinics, infection rates among people who use drugs are still high and the general knowledge on preventive measures is inadequate."8.02Seroprevalence of hepatitis B virus infection, anti-HCV antibodies and HIV and knowledge among people who use drugs attending methadone therapy clinic in Tanzania; a cross-sectional study. ( Bakshi, FA; Gunda, DW; Jaka, H; Kalokola, F; Kilonzo, SB; Majinge, DC; Manyiri, PM; Mtui, G; Shao, ER; Stephano, A, 2021)
"This study investigates the prevalence and correlates of hepatitis C virus (HCV) infections among heroin dependent individuals who received methadone maintenance therapy in Taiwan."7.79High prevalence but low awareness of hepatitis C virus infection among heroin users who received methadone maintenance therapy in Taiwan. ( Chang, TJ; Chen, VC; Chou, JY; Gossop, M; Lee, PC; Lin, TY; Ng, MH; Shao, WC, 2013)
"The survey of viral infections in the liver investigated by means of serological markers of hepatitis A, B and C in drug addicts on methadone maintenance treatment is important for the next procedures."7.72[Prevalence of serological markers of viral hepatitis B and hepatitis C in drug-dependent individuals treated at the Drop Methadone Center in Prague]. ( Urbánek, P; Wilczek, H, 2003)
"The prevalence of human immunodeficiency virus (HIV) infection and hepatitis B, C, and G virus infections was determined in a selected group of 40 intravenous drug addicts on methadone maintenance treatment."7.72Prevalence of HIV, hepatitis B, C and G virus infections among injecting drug users on methadone maintenance treatment in Maribor. ( Baklan, Z; Gorisek, JR; Pisec, A; Poljak, M, 2004)
"The high rates of hepatitis B exposure in injecting drug users on methadone treatment confirm the need for hepatitis B vaccination, particularly in view of their endemic hepatitis C infection."7.71Prevalence of hepatitis B and C infection in a methadone clinic population: implications for hepatitis B vaccination. ( Carter, H; Hailwood, C; Hanlon, C; Massarotto, A; Robinson, G, 2001)
"To study the efficacy of standard hepatitis B (HB) vaccination in methadone-maintained former intravenous drug users."7.70Methadone-maintained former heroin addicts, including those who are anti-HIV-1 seropositive, comply with and respond to hepatitis B vaccination. ( Bergasa, NV; Borg, L; Ho, A; Khuri, E; Kreek, MJ; Melia, D; Wells, A, 1999)
" We studied the associations between retention in methadone treatment and drug use behaviors and incidence of hepatitis B and C in a cohort of IDUs in the Seattle, Washington, area."7.70Methadone treatment and HIV and hepatitis B and C risk reduction among injectors in the Seattle area. ( Hagan, H; Murrill, CS; Thiede, H, 2000)
"We explored the long-term immunogenicity induced by 60 μg and 20 μg hepatitis B vaccines among patients receiving methadone maintenance treatment (MMT)."5.34Long-term durability of immunogenicity induced by standard and triple-dose hepatitis B vaccine in patients receiving methadone maintenance treatment. ( Dong, S; Feng, D; Feng, Y; Gao, L; Liang, X; Shao, Z; Shi, J; Shi, S; Wang, S; Wu, L; Wu, Y; Yao, T; Zhang, Y, 2020)
"To explore whether the immunization with high-dose (60μg) hepatitis B vaccines in patients receiving methadone maintenance treatment (MMT) could yield a superior protection against hepatitis B infection than did the standard dose (20μg)."5.24Immunogenicity and safety of a high-dose hepatitis B vaccine among patients receiving methadone maintenance treatment: A randomized, double-blinded, parallel-controlled trial. ( Feng, D; Feng, Y; Gao, L; Liang, X; Shi, J; Shi, S; Wang, S; Yao, T; Zhang, Y, 2017)
"We evaluated the efficacy of a hepatitis care coordination intervention to improve linkage to hepatitis A virus (HAV) and hepatitis B virus (HBV) vaccination and clinical evaluation of hepatitis C virus (HCV) infection among methadone maintenance patients."5.17A randomized trial of a hepatitis care coordination model in methadone maintenance treatment. ( Bodenheimer, HC; Coffin, L; Delucchi, KL; Des Jarlais, DC; Hall, J; Hammer, H; Hengl, NS; Hettema, J; Jordan, AE; Khalili, M; Manuel, JK; Masson, CL; McKnight, C; Min, A; Pepper, N; Perlman, DC; Seewald, RM; Shapiro, B; Shopshire, MS; Sorensen, JL; Young, C, 2013)
"This randomized, controlled study (n = 256) was conducted to compare three interventions designed to promote hepatitis A virus (HAV) and hepatitis B virus (HBV) vaccination completion, among clients undergoing methadone maintenance treatment (MMT) in Los Angeles and Santa Monica."5.14Predictors of hepatitis knowledge improvement among methadone maintained clients enrolled in a hepatitis intervention program. ( Cohen, A; Greengold, B; Marfisee, M; Nyamathi, A; Sinha, K; Tyler, D, 2010)
"Despite the efforts to curb viral hepatitis and HIV infections through Methadone clinics, infection rates among people who use drugs are still high and the general knowledge on preventive measures is inadequate."4.02Seroprevalence of hepatitis B virus infection, anti-HCV antibodies and HIV and knowledge among people who use drugs attending methadone therapy clinic in Tanzania; a cross-sectional study. ( Bakshi, FA; Gunda, DW; Jaka, H; Kalokola, F; Kilonzo, SB; Majinge, DC; Manyiri, PM; Mtui, G; Shao, ER; Stephano, A, 2021)
"This study investigates the prevalence and correlates of hepatitis C virus (HCV) infections among heroin dependent individuals who received methadone maintenance therapy in Taiwan."3.79High prevalence but low awareness of hepatitis C virus infection among heroin users who received methadone maintenance therapy in Taiwan. ( Chang, TJ; Chen, VC; Chou, JY; Gossop, M; Lee, PC; Lin, TY; Ng, MH; Shao, WC, 2013)
"The survey of viral infections in the liver investigated by means of serological markers of hepatitis A, B and C in drug addicts on methadone maintenance treatment is important for the next procedures."3.72[Prevalence of serological markers of viral hepatitis B and hepatitis C in drug-dependent individuals treated at the Drop Methadone Center in Prague]. ( Urbánek, P; Wilczek, H, 2003)
"The prevalence of human immunodeficiency virus (HIV) infection and hepatitis B, C, and G virus infections was determined in a selected group of 40 intravenous drug addicts on methadone maintenance treatment."3.72Prevalence of HIV, hepatitis B, C and G virus infections among injecting drug users on methadone maintenance treatment in Maribor. ( Baklan, Z; Gorisek, JR; Pisec, A; Poljak, M, 2004)
"The high rates of hepatitis B exposure in injecting drug users on methadone treatment confirm the need for hepatitis B vaccination, particularly in view of their endemic hepatitis C infection."3.71Prevalence of hepatitis B and C infection in a methadone clinic population: implications for hepatitis B vaccination. ( Carter, H; Hailwood, C; Hanlon, C; Massarotto, A; Robinson, G, 2001)
" The descriptive analysis in heroin-assisted treatment showed a reduction in infection risk for viral hepatitis corresponding to the lower risk behaviour of patients."3.71HIV and hepatitis virus infections among injecting drug users in a medically controlled heroin prescription programme. ( Blättler, R; Gutzwiller, F; Steffen, T; Zwahlen, M, 2001)
"To study the efficacy of standard hepatitis B (HB) vaccination in methadone-maintained former intravenous drug users."3.70Methadone-maintained former heroin addicts, including those who are anti-HIV-1 seropositive, comply with and respond to hepatitis B vaccination. ( Bergasa, NV; Borg, L; Ho, A; Khuri, E; Kreek, MJ; Melia, D; Wells, A, 1999)
" We studied the associations between retention in methadone treatment and drug use behaviors and incidence of hepatitis B and C in a cohort of IDUs in the Seattle, Washington, area."3.70Methadone treatment and HIV and hepatitis B and C risk reduction among injectors in the Seattle area. ( Hagan, H; Murrill, CS; Thiede, H, 2000)
" The average DAM dosage was 274."2.72Controlled trial of prescribed heroin in the treatment of opioid addiction. ( Carrasco, F; March, JC; Oviedo-Joekes, E; Perea-Milla, E, 2006)
" Clinically significant MDIs included withdrawal symptoms, which were found among MMTP patients co-administered with buprenorphine or tramadol; severe QTc prolongation effect, which might be associated with use of haloperidol or droperidol; and additive CNS and respiratory depression, which could result from use of methadone in combination with chlorpromazine or thioridazine."1.38Survey of methadone-drug interactions among patients of methadone maintenance treatment program in Taiwan. ( Lee, HY; Li, JH; Tang, HP; Wu, JS; Wu, LT; Yen, CF, 2012)
"Methadone maintenance treatment of opiate addiction is highly effective at reducing drug use, drug-related criminal activity, and risk of HIV transmission."1.33Linkage with methadone treatment upon release from incarceration: a promising opportunity. ( Clarke, J; Key, RG; McKenzie, M; Poshkus, M; Rich, JD; Shield, DC; Wolf, FA, 2005)
"We evaluated the medical histories, drug abuse patterns, sexual behaviors, serological studies for syphilis and hepatitis B infection and other laboratory studies in 1780 patients enrolled in New York City drug treatment clinics in 1987."1.29Medical disorders in a cohort of New York city drug abusers: much more than HIV disease. ( Ajuluchukwu, DC; Bailey, J; Brown, LS; Hickson, MJ, 1993)

Research

Studies (43)

TimeframeStudies, this research(%)All Research%
pre-19906 (13.95)18.7374
1990's6 (13.95)18.2507
2000's14 (32.56)29.6817
2010's13 (30.23)24.3611
2020's4 (9.30)2.80

Authors

AuthorsStudies
Feng, Y3
Yao, T4
Gao, Y2
Li, H5
Dong, S3
Wu, Y4
Liu, Y8
Li, J8
Liu, C3
Liu, J5
Xue, T1
Yuan, Y2
Wu, J2
Wang, F2
Liang, X4
Wang, S3
Jiménez-Treviño, L2
Martínez-Cao, C1
Sánchez-Lasheras, F2
Iglesias, C1
Antuña, MJ1
Riera, L1
Sáiz-Martínez, PA1
Bobes, J2
Halim, AA1
Alsayed, B1
Embarak, S1
Yaseen, T1
Dabbous, S1
Fontaine, O1
Dueluzeau, R1
Raibaud, P1
Chabanet, C1
Popoff, MR1
Badoual, J1
Gabilan, JC1
Andremont, A1
Gómez, L1
Andrés, S1
Sánchez, J1
Alonso, JM1
Rey, J1
López, F1
Jiménez, A1
Yan, Z1
Zhou, L1
Zhao, Y3
Wang, J6
Huang, L2
Hu, K1
Liu, H4
Wang, H3
Guo, Z1
Song, Y1
Huang, H4
Yang, R1
Owen, TW1
Al-Kaysi, RO1
Bardeen, CJ1
Cheng, Q1
Wu, S1
Cheng, T1
Zhou, X1
Wang, B4
Zhang, Q4
Wu, X2
Yao, Y3
Ochiai, T1
Ishiguro, H2
Nakano, R2
Kubota, Y2
Hara, M1
Sunada, K1
Hashimoto, K1
Kajioka, J1
Fujishima, A1
Jiao, J3
Gai, QY3
Wang, W2
Zang, YP2
Niu, LL2
Fu, YJ3
Wang, X4
Yao, LP1
Qin, QP1
Wang, ZY1
Aleksic Sabo, V1
Knezevic, P1
Borges-Argáez, R1
Chan-Balan, R1
Cetina-Montejo, L1
Ayora-Talavera, G1
Sansores-Peraza, P1
Gómez-Carballo, J1
Cáceres-Farfán, M1
Jang, J1
Akin, D1
Bashir, R1
Yu, Z1
Zhu, J2
Jiang, H1
He, C2
Xiao, Z1
Xu, J2
Sun, Q1
Han, D1
Lei, H1
Zhao, K2
Zhu, L1
Li, X4
Fu, H2
Wilson, BK1
Step, DL1
Maxwell, CL1
Gifford, CA1
Richards, CJ1
Krehbiel, CR1
Warner, JM1
Doerr, AJ1
Erickson, GE1
Guretzky, JA1
Rasby, RJ1
Watson, AK1
Klopfenstein, TJ1
Sun, Y4
Liu, Z3
Pham, TD1
Lee, BK1
Yang, FC1
Wu, KH1
Lin, WP1
Hu, MK1
Lin, L3
Shao, J1
Sun, M1
Xu, G1
Zhang, X6
Xu, N1
Wang, R1
Liu, S1
He, H1
Dong, X2
Yang, M2
Yang, Q1
Duan, S1
Yu, Y2
Han, J2
Zhang, C3
Chen, L2
Yang, X1
Li, W3
Wang, T2
Campbell, DA1
Gao, K1
Zager, RA1
Johnson, ACM1
Guillem, A1
Keyser, J1
Singh, B1
Steubl, D1
Schneider, MP1
Meiselbach, H1
Nadal, J1
Schmid, MC1
Saritas, T1
Krane, V1
Sommerer, C1
Baid-Agrawal, S1
Voelkl, J1
Kotsis, F1
Köttgen, A1
Eckardt, KU1
Scherberich, JE1
Yao, L2
Sun, L3
Zhu, Z1
Naren, N1
Zhang, XX2
Gentile, GL1
Rupert, AS1
Carrasco, LI1
Garcia, EM1
Kumar, NG1
Walsh, SW1
Jefferson, KK1
Guest, RL1
Samé Guerra, D1
Wissler, M1
Grimm, J1
Silhavy, TJ1
Lee, JH2
Yoo, JS1
Kim, Y1
Kim, JS2
Lee, EJ1
Roe, JH1
Delorme, M1
Bouchard, PA1
Simon, M1
Simard, S1
Lellouche, F1
D'Urzo, KA1
Mok, F1
D'Urzo, AD1
Koneru, B1
Lopez, G1
Farooqi, A1
Conkrite, KL1
Nguyen, TH1
Macha, SJ1
Modi, A1
Rokita, JL1
Urias, E1
Hindle, A1
Davidson, H1
Mccoy, K1
Nance, J1
Yazdani, V1
Irwin, MS1
Yang, S1
Wheeler, DA1
Maris, JM1
Diskin, SJ1
Reynolds, CP1
Abhilash, L1
Kalliyil, A1
Sheeba, V1
Hartley, AM2
Meunier, B2
Pinotsis, N1
Maréchal, A2
Xu, JY1
Genko, N1
Haraux, F1
Rich, PR1
Kamalanathan, M1
Doyle, SM1
Xu, C1
Achberger, AM1
Wade, TL1
Schwehr, K1
Santschi, PH1
Sylvan, JB1
Quigg, A1
Leong, W1
Xu, W2
Gao, S1
Zhai, X1
Wang, C2
Gilson, E1
Ye, J1
Lu, Y1
Yan, R1
Zhang, Y8
Hu, Z1
You, Q1
Cai, Q1
Yang, D1
Gu, S1
Dai, H1
Zhao, X1
Gui, C1
Gui, J1
Wu, PK1
Hong, SK1
Starenki, D1
Oshima, K1
Shao, H1
Gestwicki, JE1
Tsai, S1
Park, JI1
Wang, Y7
Zhao, R1
Gu, Z1
Dong, C2
Guo, G1
Li, L4
Barrett, HE1
Meester, EJ1
van Gaalen, K1
van der Heiden, K1
Krenning, BJ1
Beekman, FJ1
de Blois, E1
de Swart, J1
Verhagen, HJ1
Maina, T1
Nock, BA1
Norenberg, JP1
de Jong, M1
Gijsen, FJH1
Bernsen, MR1
Martínez-Milla, J1
Galán-Arriola, C1
Carnero, M1
Cobiella, J1
Pérez-Camargo, D1
Bautista-Hernández, V1
Rigol, M1
Solanes, N1
Villena-Gutierrez, R1
Lobo, M1
Mateo, J1
Vilchez-Tschischke, JP1
Salinas, B1
Cussó, L1
López, GJ1
Fuster, V1
Desco, M1
Sanchez-González, J1
Ibanez, B1
van den Berg, P1
Schweitzer, DH1
van Haard, PMM1
Geusens, PP1
van den Bergh, JP1
Zhu, X1
Huang, X2
Xu, H3
Yang, G2
Lin, Z1
Salem, HF1
Nafady, MM1
Kharshoum, RM1
Abd El-Ghafar, OA1
Farouk, HO1
Domiciano, D1
Nery, FC1
de Carvalho, PA1
Prudente, DO1
de Souza, LB1
Chalfun-Júnior, A1
Paiva, R1
Marchiori, PER1
Lu, M2
An, Z1
Jiang, J2
Du, S1
Zhou, H1
Cui, J1
Wu, W1
Song, J1
Lian, Q1
Uddin Ahmad, Z1
Gang, DD1
Konggidinata, MI1
Gallo, AA1
Zappi, ME1
Yang, TWW1
Johari, Y1
Burton, PR1
Earnest, A1
Shaw, K1
Hare, JL1
Brown, WA1
Kim, GA1
Han, S1
Choi, GH1
Choi, J1
Lim, YS1
Gallo, A1
Cancelli, C1
Ceron, E1
Covino, M1
Capoluongo, E1
Pocino, K1
Ianiro, G1
Cammarota, G1
Gasbarrini, A1
Montalto, M1
Somasundar, Y1
Lu, IC1
Mills, MR1
Qian, LY1
Olivares, X1
Ryabov, AD1
Collins, TJ1
Zhao, L1
Doddipatla, S1
Thomas, AM1
Nikolayev, AA1
Galimova, GR1
Azyazov, VN1
Mebel, AM1
Kaiser, RI1
Guo, S1
Yang, P1
Yu, X2
Zhang, H1
Yu, B2
Han, B1
George, MW1
Moor, MB1
Bonny, O1
Langenberg, E1
Paik, H1
Smith, EH1
Nair, HP1
Hanke, I1
Ganschow, S1
Catalan, G1
Domingo, N1
Schlom, DG1
Assefa, MK1
Wu, G2
Hayton, TW1
Becker, B1
Enikeev, D1
Netsch, C1
Gross, AJ1
Laukhtina, E1
Glybochko, P1
Rapoport, L1
Herrmann, TRW1
Taratkin, M1
Dai, W1
Shi, J4
Carreno, J1
Kloner, RA1
Pickersgill, NA1
Vetter, JM1
Kim, EH1
Cope, SJ1
Du, K1
Venkatesh, R1
Giardina, JD1
Saad, NES1
Bhayani, SB1
Figenshau, RS1
Eriksson, J1
Landfeldt, E1
Ireland, S1
Jackson, C1
Wyatt, E1
Gaudig, M1
Stancill, JS1
Happ, JT1
Broniowska, KA1
Hogg, N1
Corbett, JA1
Tang, LF1
Bi, YL1
Fan, Y2
Sun, YB1
Wang, AL1
Xiao, BH1
Wang, LF1
Qiu, SW1
Guo, SW1
Wáng, YXJ1
Sun, J2
Chu, S1
Pan, Q1
Li, D2
Zheng, S2
Ma, L1
Wang, L3
Hu, T1
Han, Z1
Yin, Z1
Ge, X1
Xie, K1
Lei, P1
Dias-Santagata, D1
Lennerz, JK1
Sadow, PM1
Frazier, RP1
Govinda Raju, S1
Henry, D1
Chung, T1
Kherani, J1
Rothenberg, SM1
Wirth, LJ1
Marti, CN1
Choi, NG1
Bae, SJ1
Ni, L1
Luo, X1
Dai, T1
Yang, Y3
Lee, R1
Fleischer, AS1
Wemhoff, AP1
Ford, CR1
Kleppinger, EL1
Helms, K1
Bush, AA1
Luna-Abanto, J1
García Ruiz, L1
Laura Martinez, J1
Álvarez Larraondo, M1
Villoslada Terrones, V1
Dukic, L1
Maric, N1
Simundic, AM1
Chogtu, B1
Ommurugan, B1
Thomson, SR1
Kalthur, SG1
Benidir, M1
El Massoudi, S1
El Ghadraoui, L1
Lazraq, A1
Benjelloun, M1
Errachidi, F1
Cassar, M1
Law, AD1
Chow, ES1
Giebultowicz, JM1
Kretzschmar, D1
Salonurmi, T1
Nabil, H1
Ronkainen, J1
Hyötyläinen, T1
Hautajärvi, H1
Savolainen, MJ1
Tolonen, A1
Orešič, M1
Känsäkoski, P1
Rysä, J1
Hakkola, J1
Hukkanen, J1
Zhu, N1
Li, Y4
Du, Q1
Hao, P1
Cao, X1
Li, CX1
Zhao, S1
Luo, XM1
Feng, JX1
Gonzalez-Cotto, M1
Guo, L1
Karwan, M1
Sen, SK1
Barb, J1
Collado, CJ1
Elloumi, F1
Palmieri, EM1
Boelte, K1
Kolodgie, FD1
Finn, AV1
Biesecker, LG1
McVicar, DW1
Qu, F1
Deng, Z1
Xie, Y2
Tang, J3
Chen, Z2
Luo, W1
Xiong, D1
Zhao, D1
Fang, J1
Zhou, Z1
Niu, PP1
Song, B1
Xu, YM1
Zhang, Z2
Qiu, N1
Yin, J1
Zhang, J3
Guo, W1
Liu, M2
Liu, T2
Chen, D5
Luo, K1
He, Z2
Zheng, G1
Xu, F1
Sun, W1
Yin, F1
van Hest, JCM1
Du, L2
Shi, X1
Kang, S1
Duan, W1
Zhang, S2
Feng, J2
Qi, N1
Shen, G1
Ren, H1
Shang, Q1
Zhao, W2
Yang, Z2
Jiang, X2
Alame, M1
Cornillot, E1
Cacheux, V1
Tosato, G1
Four, M1
De Oliveira, L1
Gofflot, S1
Delvenne, P1
Turtoi, E1
Cabello-Aguilar, S1
Nishiyama, M1
Turtoi, A1
Costes-Martineau, V1
Colinge, J1
Guo, Q1
Quan, M1
Dong, J1
Bai, J1
Han, R1
Cai, Y1
Lv, YQ1
Chen, Q1
Lyu, HD1
Deng, L1
Zhou, D1
Xiao, X1
De Langhe, S1
Billadeau, DD1
Lou, Z1
Zhang, JS1
Xue, Z1
Shen, XD1
Gao, F1
Busuttil, RW1
Kupiec-Weglinski, JW1
Ji, H1
Otano, I1
Alvarez, M1
Minute, L1
Ochoa, MC1
Migueliz, I1
Molina, C1
Azpilikueta, A1
de Andrea, CE1
Etxeberria, I1
Sanmamed, MF1
Teijeira, Á1
Berraondo, P1
Melero, I1
Zhong, Z1
Xie, X1
Yu, Q1
Zhou, C1
Liu, W1
Chen, W1
Yin, Y1
Li, CW1
Hsu, JL1
Zhou, Q1
Hu, B1
Fu, P1
Atyah, M1
Ma, Q2
Xu, Y1
Dong, Q1
Hung, MC1
Ren, N1
Huang, P1
Liao, R1
Chen, X3
Cao, Q1
Yuan, X1
Nie, W1
Yang, J2
Shao, B1
Ma, X1
Bi, Z1
Tie, Y1
Mo, F1
Xie, D1
Wei, Y1
Wei, X2
Dokla, EME1
Fang, CS1
Chu, PC1
Chang, CS1
Abouzid, KAM1
Chen, CS1
Blaszczyk, R1
Brzezinska, J1
Dymek, B1
Stanczak, PS1
Mazurkiewicz, M1
Olczak, J1
Nowicka, J1
Dzwonek, K1
Zagozdzon, A1
Golab, J1
Golebiowski, A1
Xin, Z1
Himmelbauer, MK1
Jones, JH1
Enyedy, I1
Gilfillan, R1
Hesson, T1
King, K1
Marcotte, DJ1
Murugan, P1
Santoro, JC1
Gonzalez-Lopez de Turiso, F1
Pedron, J1
Boudot, C1
Brossas, JY1
Pinault, E1
Bourgeade-Delmas, S1
Sournia-Saquet, A1
Boutet-Robinet, E1
Destere, A1
Tronnet, A1
Bergé, J1
Bonduelle, C1
Deraeve, C1
Pratviel, G1
Stigliani, JL1
Paris, L1
Mazier, D1
Corvaisier, S1
Since, M1
Malzert-Fréon, A1
Wyllie, S1
Milne, R1
Fairlamb, AH1
Valentin, A1
Courtioux, B1
Verhaeghe, P1
Fang, X1
Gao, M1
Gao, H1
Bi, W1
Tang, H1
Cui, Y1
Zhang, L3
Fan, H1
Yu, H1
Mathison, CJN1
Chianelli, D1
Rucker, PV1
Nelson, J1
Roland, J1
Huang, Z2
Xie, YF1
Epple, R1
Bursulaya, B1
Lee, C1
Gao, MY1
Shaffer, J1
Briones, S1
Sarkisova, Y1
Galkin, A1
Li, N1
Li, C2
Hua, S1
Kasibhatla, S1
Kinyamu-Akunda, J1
Kikkawa, R1
Molteni, V1
Tellew, JE1
Jin, X1
Pang, B1
Liu, Q2
Liu, X3
Huang, Y2
Josephine Fauci, A1
Ma, Y1
Soo Lee, M1
Yuan, W1
Gao, R1
Qi, H1
Zheng, W1
Yang, F2
Chua, H1
Wang, K1
Ou, Y1
Huang, M1
Zhu, Y1
Yu, J1
Tian, J1
Zhao, M2
Hu, J1
Yao, C1
Zhang, B1
Usawachintachit, M1
Tzou, DT1
Washington, SL1
Hu, W1
Chi, T1
Sorensen, MD1
Bailey, MR1
Hsi, RS1
Cunitz, BW1
Simon, J1
Wang, YN1
Dunmire, BL1
Paun, M1
Starr, F1
Lu, W1
Evan, AP1
Harper, JD1
Han, G1
Rodrigues, AE1
Fouladvand, F1
Falahi, E1
Asbaghi, O1
Abbasnezhad, A1
Anigboro, AA1
Avwioroko, OJ1
Cholu, CO1
Sonei, A1
Fazelipour, S1
Kanaani, L1
Jahromy, MH1
Jo, K1
Hong, KB1
Suh, HJ1
Park, JH1
Shin, E1
Park, E1
Kouakou-Kouamé, CA1
N'guessan, FK1
Montet, D1
Djè, MK1
Kim, GD1
González-Fernández, D1
Pons, EDC1
Rueda, D1
Sinisterra, OT1
Murillo, E1
Scott, ME1
Koski, KG1
Shete, PB1
Gonzales, R1
Ackerman, S1
Cattamanchi, A1
Handley, MA1
Li, XX1
Xiao, SZ1
Gu, FF1
He, WP1
Ni, YX1
Han, LZ1
Heffernan, JK1
Valgepea, K1
de Souza Pinto Lemgruber, R1
Casini, I1
Plan, M1
Tappel, R1
Simpson, SD1
Köpke, M1
Nielsen, LK1
Marcellin, E1
Cen, YK1
Lin, JG1
Wang, YL1
Wang, JY1
Liu, ZQ1
Zheng, YG1
Spirk, D1
Noll, S1
Burnier, M1
Rimoldi, S1
Noll, G1
Sudano, I1
Penzhorn, BL1
Oosthuizen, MC1
Kobos, LM1
Alqatani, S1
Ferreira, CR1
Aryal, UK1
Hedrick, V1
Sobreira, TJP1
Shannahan, JH1
Gale, P1
Singhroy, DN1
MacLean, E1
Kohli, M1
Lessem, E1
Branigan, D1
England, K1
Suleiman, K1
Drain, PK1
Ruhwald, M1
Schumacher, S1
Denkinger, CM1
Waning, B1
Van Gemert, W1
Pai, M1
Myers, RK1
Bonsu, JM1
Carey, ME1
Yerys, BE1
Mollen, CJ1
Curry, AE1
Douglas, TA1
Alinezhadbalalami, N1
Balani, N1
Schmelz, EM1
Davalos, RV1
Kamaldinov, T1
Erndt-Marino, J1
Levin, M1
Kaplan, DL1
Hahn, MS1
Heidarimoghadam, R1
Farmany, A1
Lee, JJ1
Kang, J1
Park, S1
Cho, JH1
Oh, S1
Park, DJ1
Perez-Maldonado, R1
Cho, JY1
Park, IH1
Kim, HB1
Song, M1
Mfarrej, B1
Jofra, T1
Morsiani, C1
Gagliani, N1
Fousteri, G1
Battaglia, M1
Giuliano, C1
Levinger, I1
Vogrin, S1
Neil, CJ1
Allen, JD1
Lv, Y1
Yuan, R1
Cai, B1
Bahrami, B1
Chowdhury, AH1
Yang, C2
Qiao, Q1
Liu, SF1
Zhang, WH1
Kolano, L1
Knappe, D1
Volke, D1
Sträter, N1
Hoffmann, R1
Coussens, M1
Calders, P1
Lapauw, B1
Celie, B1
Banica, T1
De Wandele, I1
Pacey, V1
Malfait, F1
Rombaut, L1
Vieira, D1
Angel, S1
Honjol, Y1
Gruenheid, S1
Gbureck, U1
Harvey, E1
Merle, G1
Seo, G1
Lee, G1
Kim, MJ1
Baek, SH1
Choi, M1
Ku, KB1
Lee, CS1
Jun, S1
Park, D1
Kim, HG1
Kim, SJ1
Lee, JO1
Kim, BT1
Park, EC1
Kim, SI1
Ende, M1
Kirkkala, T1
Loitzenbauer, M1
Talla, D1
Wildner, M1
Miletich, R1
Criado, A1
Lavela, P1
Tirado, JL1
Pérez-Vicente, C1
Kang, D1
Feng, D4
Fang, Z1
Wei, F1
De Clercq, E1
Pannecouque, C1
Zhan, P1
Guo, Y1
Shen, Y1
Wang, Q2
Kawazoe, Y1
Jena, P1
Sun, Z1
Li, Z2
Liang, H1
Xu, X1
Ma, G1
Huo, X1
Church, JS1
Chace-Donahue, F1
Blum, JL1
Ratner, JR1
Zelikoff, JT1
Schwartzer, JJ1
Fiseha, T1
Tamir, Z1
Yao, W1
Wang, P1
Mi, K1
Cheng, J1
Gu, C1
Huang, J2
Sun, HB1
Xing, WQ1
Liu, XB1
Zheng, Y1
Yang, SJ1
Wang, ZF1
Liu, SL1
Ba, YF1
Zhang, RX1
Liu, BX1
Fan, CC1
Chen, PN1
Liang, GH1
Yu, YK1
Wang, HR1
Li, HM1
Li, ZX1
Lalani, SS1
Anasir, MI1
Poh, CL1
Khan, IT1
Nadeem, M1
Imran, M1
Khalique, A1
Raspini, B1
Porri, D1
De Giuseppe, R1
Chieppa, M1
Liso, M1
Cerbo, RM1
Civardi, E1
Garofoli, F1
Monti, MC1
Vacca, M1
De Angelis, M1
Cena, H1
Kong, D1
Han, X1
Zhou, Y3
Xue, H1
Zhang, W1
Ruan, Z1
Li, S2
Noer, PR1
Kjaer-Sorensen, K1
Juhl, AK1
Goldstein, A1
Ke, C1
Oxvig, C1
Duan, C1
Kong, F1
Lin, S1
Wang, Z2
Bhattacharya, R1
Mazumder, D1
Yan, X1
Ma, C1
Tang, Y1
Kong, X1
Lu, J1
Zhang, M1
Vital-Jacome, M1
Cazares-Granillo, M1
Carrillo-Reyes, J1
Buitron, G1
Jacob, SI1
Douair, I1
Maron, L1
Ménard, G1
Rusjan, P1
Sabioni, P1
Di Ciano, P1
Mansouri, E1
Boileau, I1
Laveillé, A1
Capet, M1
Duvauchelle, T1
Schwartz, JC1
Robert, P1
Le Foll, B1
Xia, Y1
Chen, S1
Luo, M1
Cai, S1
He, Y2
Garbacz, P1
Misiak, M1
Jackowski, K1
Yuan, Q1
Sherrell, PC1
Chen, J2
Bi, X1
Nutho, B1
Mahalapbutr, P1
Hengphasatporn, K1
Pattaranggoon, NC1
Simanon, N1
Shigeta, Y1
Hannongbua, S1
Rungrotmongkol, T1
Caffrey, PJ1
Kher, R1
Bian, K1
Delaney, S1
Xue, J1
Wu, P1
Xu, L1
Luo, J1
Ye, S1
Ustriyana, P1
Wei, B1
Raee, E1
Hu, Y1
Wesdemiotis, C1
Sahai, N1
Kaur, A1
Nigam, K1
Srivastava, S1
Tyagi, A1
Dang, S1
Millar, JE1
Bartnikowski, N1
Passmore, MR1
Obonyo, NG1
Malfertheiner, MV1
von Bahr, V1
Redd, MA1
See Hoe, L1
Ki, KK1
Pedersen, S1
Boyle, AJ1
Baillie, JK1
Shekar, K1
Palpant, N1
Suen, JY1
Matthay, MA1
McAuley, DF1
Fraser, JF1
Settles, JA1
Gerety, GF1
Spaepen, E1
Suico, JG1
Child, CJ1
Oh, BL1
Lee, JS1
Lee, EY1
Lee, HY2
Yu, HG1
Leslie, I1
Boos, LA1
Larkin, J1
Pickering, L1
Lima, HK1
Vogel, K1
Hampel, D1
Wagner-Gillespie, M1
Fogleman, AD1
Ferraz, SL1
O'Connor, M1
Mazzucchelli, TG1
Kajiyama, H1
Suzuki, S1
Shimbo, A1
Utsumi, F1
Yoshikawa, N1
Kikkawa, F1
Javvaji, PK1
Dhali, A1
Francis, JR1
Kolte, AP1
Roy, SC1
Selvaraju, S1
Mech, A1
Sejian, V1
DeSilva, S1
Vaidya, SS1
Mao, C1
Akhatayeva, Z1
Cheng, H1
Zhang, G1
Jiang, F1
Meng, X1
Elnour, IE1
Lan, X1
Song, E1
Rohde, S1
Antonides, CFJ1
Muslem, R1
de Woestijne, PCV1
der Meulen, MHV1
Kraemer, US1
Dalinghaus, M1
Bogers, AJJC1
Pourmand, A1
Ghassemi, M1
Sumon, K1
Amini, SB1
Hood, C1
Sikka, N1
Duan, H1
Chen, WP1
Fan, M1
Wang, WP1
Yu, L1
Tan, SJ1
Xin, S1
Wan, LJ1
Guo, YG1
Tanda, S1
Gingl, K1
Ličbinský, R1
Hegrová, J1
Goessler, W1
Li, ZL1
Zhou, YL1
Yan, W1
Luo, L1
Su, ZZ1
Fan, MZ1
Wang, SR1
Zhao, WG1
Xu, D1
Hassan, HM1
Jiang, Z1
Bachmann, KF1
Haenggi, M1
Jakob, SM1
Takala, J1
Gattinoni, L1
Berger, D1
Bentley, RF1
Vecchiarelli, E1
Banks, L1
Gonçalves, PEO1
Thomas, SG1
Goodman, JM1
Mather, K1
Boachie, R1
Anini, Y1
Panahi, S1
Anderson, GH1
Luhovyy, BL1
Nafie, MS1
Arafa, K1
Sedky, NK1
Alakhdar, AA1
Arafa, RK1
Fan, S1
Hu, H1
Liang, J1
Hu, BC1
Wen, Z1
Hu, D1
Liu, YY1
Chu, Q1
Wu, MC1
Lu, X1
Wang, D1
Hu, M1
Shen, H1
Yao, M1
Dahlgren, RA1
Vysloužil, J1
Kulich, P1
Zeman, T1
Vaculovič, T1
Tvrdoňová, M1
Mikuška, P1
Večeřa, Z1
Stráská, J1
Moravec, P1
Balcar, VJ1
Šerý, O1
Qiao, L1
Xiong, X1
Peng, X1
Zheng, J1
Duan, J1
Xiao, W1
Zhou, HY1
Sui, ZY1
Zhao, FL1
Sun, YN1
Wang, HY1
Han, BH1
Jintao, X1
Shasha, Y1
Jincai, W1
Chunyan, L1
Mengya, Y1
Yongli, S1
Rasoanirina, BNV1
Lassoued, MA1
Miladi, K1
Razafindrakoto, Z1
Chaâbane-Banaoues, R1
Ramanitrahasimbola, D1
Cornet, M1
Sfar, S1
Liang, C1
Xing, Q1
Yi, JL1
Zhang, YQ1
Li, CY1
Tang, SJ1
Gao, C1
Sun, X1
Peng, M1
Sun, XF1
Zhang, T1
Shi, JH1
Liao, CX1
Gao, WJ1
Sun, LL1
Cao, WH1
Lyu, J1
Yu, CQ1
Wang, SF1
Pang, ZC1
Cong, LM1
Dong, Z1
Wu, F1
Wu, XP1
Jiang, GH1
Wang, XJ1
Wang, BY1
Li, LM1
Pan, L1
Wan, SP1
Yi, HWL1
He, HJ1
Yong, ZP1
Shan, GL1
Weng, TT1
Yan, SQ1
Gao, GP1
Wei, C1
Tao, FB1
Shao, ZH1
Shi, S3
Feng, YL1
Zhang, YW1
Wang, SP1
Shi, AX1
Operario, D1
Zhang, ZH1
Zhu, XF1
Zaller, N1
Gao, P1
Sun, YH1
Zhang, HB1
Gao, L2
Shao, Z1
Wu, L1
Kilonzo, SB1
Gunda, DW1
Majinge, DC1
Jaka, H1
Manyiri, PM1
Kalokola, F1
Mtui, G1
Shao, ER1
Bakshi, FA1
Stephano, A1
Ng, MH1
Chou, JY1
Chang, TJ1
Lee, PC1
Shao, WC1
Lin, TY1
Chen, VC1
Gossop, M1
Masson, CL3
Delucchi, KL2
McKnight, C3
Hettema, J2
Khalili, M2
Min, A2
Jordan, AE3
Pepper, N1
Hall, J1
Hengl, NS1
Young, C3
Shopshire, MS2
Manuel, JK1
Coffin, L1
Hammer, H1
Shapiro, B1
Seewald, RM2
Bodenheimer, HC1
Sorensen, JL3
Des Jarlais, DC3
Perlman, DC3
Larios, SE1
Hengl, N1
Piralishvili, G1
Chavchanidze, M1
Gamkrelidze, I1
Nikolaishvili, N1
Sepúlveda-Arias, JC1
Isaza, C1
Vélez, JP1
Teoh Bing Fei, J1
Yee, A1
Habil, MH1
Danaee, M1
Nyamathi, A1
Tyler, D1
Sinha, K1
Marfisee, M1
Cohen, A1
Greengold, B1
Saiz, PA1
García-Portilla, MP1
Díaz-Mesa, EM1
Burón, P1
Casares, MJ1
Marina, P1
Gutiérrez, E1
Bini, EJ1
Kritz, S1
Brown, LS2
Robinson, J1
Calsyn, D1
Alderson, D1
Tracy, K1
McAuliffe, P1
Smith, C1
Rotrosen, J1
Li, JH1
Wu, LT1
Wu, JS1
Yen, CF1
Tang, HP1
Wilczek, H1
Urbánek, P1
Baklan, Z1
Gorisek, JR1
Poljak, M1
Pisec, A1
Pelet, A2
Doll, S2
Huissoud, T2
Resplendino, J2
Besson, J2
Favrat, B2
Rich, JD1
McKenzie, M1
Shield, DC1
Wolf, FA1
Key, RG1
Poshkus, M1
Clarke, J1
Du, J1
Lu, GH1
Wang, QY1
Zhu, M1
McCoy, CB1
March, JC1
Oviedo-Joekes, E1
Perea-Milla, E1
Carrasco, F1
Cullen, W1
Stanley, J1
Langton, D1
Kelly, Y1
Bury, G1
Hartman, N1
Kreek, MJ2
Ross, A1
Khuri, E2
Millman, RB1
Rodriguez, R1
Schalm, SW1
Heÿtink, RA1
Mannaerts, H1
Vreugdenhil, A1
Hickson, MJ1
Ajuluchukwu, DC1
Bailey, J1
Van Ameijden, EJ1
Van den Hoek, JA1
Mientjes, GH1
Coutinho, RA1
Stein, GL1
Fleischman, AR1
Broers, B1
Junet, C1
Bourquin, M1
Déglon, JJ2
Perrin, L1
Hirschel, B2
Borg, L1
Wells, A1
Melia, D1
Bergasa, NV1
Ho, A1
Ebert, FW1
Thiede, H1
Hagan, H1
Murrill, CS1
Cayol, V1
Corcos, M1
Clervoy, P1
Speranza, M1
Tennant, F1
Carter, H1
Robinson, G1
Hanlon, C1
Hailwood, C1
Massarotto, A1
Steffen, T1
Blättler, R1
Gutzwiller, F1
Zwahlen, M1
Carter, EF1
Livni, N1
Steigbuegel, D1
Levu, IS1
Chamot, E1
de Saussure, P1
Perrin, LH1
Whaley, WH1
Galambos, JT1
Newman, RG1
Kagen, JG1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Prospective Study on the Immunogenicity and Persistence of Hepatitis B Vaccine in Methadone Maintenance Treatment Patients[NCT03962816]Phase 4300 participants (Anticipated)Interventional2019-05-26Not yet recruiting
Immunogenicity and Persistence of Intramuscular High Dose Recombinant Hepatitis B Vaccine in Methadone Maintenance Treatment Patients in China: a Randomized Controlled Trial[NCT02991599]Phase 4196 participants (Actual)Interventional2014-10-31Completed
Nurse Case Management to Improve Linkage to Hepatitis C Care and Treatment Initiation in HIV Co-infection: A Randomized Controlled Trial[NCT02707991]68 participants (Actual)Interventional2016-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Anti-HBs Concentration at Month 12

The measurements of anti-HBs antibodies were determined quantitatively by CMIA（ Chemiluminescent Microparticle Immunoassay ） (NCT02991599)
Timeframe: Month 12

InterventionmIU/mL (Mean)
IM 20μg Group125.9
IM 60μg Group182.2

Anti-HBs Concentration at Month 18

The measurements of anti-HBs antibodies were determined quantitatively by CMIA（ Chemiluminescent Microparticle Immunoassay ） (NCT02991599)
Timeframe: Month 18

InterventionmIU/mL (Mean)
IM 20μg Group382.2
IM 60μg Group490.5

Anti-HBs Concentration at Month 30

The measurements of anti-HBs antibodies were determined quantitatively by CMIA（ Chemiluminescent Microparticle Immunoassay ） (NCT02991599)
Timeframe: Month 30

InterventionmIU/mL (Mean)
IM 20μg Group239.9
IM 60μg Group306.4

Anti-HBs Concentration at Month 42

The measurements of anti-HBs antibodies were determined quantitatively by CMIA（ Chemiluminescent Microparticle Immunoassay ） (NCT02991599)
Timeframe: Month 42

InterventionmIU/mL (Mean)
IM 20μg Group88.6
IM 60μg Group97.7

Anti-HBs Concentration at Month 7

The measurements of anti-HBs antibodies were determined quantitatively by CMIA（ Chemiluminescent Microparticle Immunoassay ） (NCT02991599)
Timeframe: Month 7

InterventionmIU/mL (Mean)
IM 20μg Group630.4
IM 60μg Group742.9

Number and Rate of Participants With Anti-HBs High-level Response at Month 12

The measurements of anti-HBs antibodies were determined quantitatively by CMIA. and anti-HBs concentrations ≥100 mIU/mL were high-level response. (NCT02991599)
Timeframe: Month 12

InterventionParticipants (Count of Participants)
IM 20μg Group13
IM 60μg Group20

Number and Rate of Participants With Anti-HBs High-level Response at Month 18

The measurements of anti-HBs antibodies were determined quantitatively by CMIA. and anti-HBs concentrations ≥100 mIU/mL were high-level response. (NCT02991599)
Timeframe: Month 18

InterventionParticipants (Count of Participants)
IM 20μg Group9
IM 60μg Group14

Number and Rate of Participants With Anti-HBs High-level Response at Month 30

The measurements of anti-HBs antibodies were determined quantitatively by CMIA. and anti-HBs concentrations ≥100 mIU/mL were high-level response. (NCT02991599)
Timeframe: Month 30

InterventionParticipants (Count of Participants)
IM 20μg Group6
IM 60μg Group11

Number and Rate of Participants With Anti-HBs High-level Response at Month 42

The measurements of anti-HBs antibodies were determined quantitatively by CMIA. and anti-HBs concentrations ≥100 mIU/mL were high-level response. (NCT02991599)
Timeframe: Month 42

InterventionParticipants (Count of Participants)
IM 20μg Group4
IM 60μg Group8

Number and Rate of Participants With Anti-HBs High-level Response at Month 7

The measurements of anti-HBs antibodies were determined quantitatively by CMIA. and anti-HBs concentrations ≥100 mIU/ml were high-level response. (NCT02991599)
Timeframe: Month 7

InterventionParticipants (Count of Participants)
IM 20μg Group31
IM 60μg Group40

Number and Rate of Participants With Anti-HBs Seroconversion at Month 12

"The measurements of anti-HBs antibodies were determined quantitatively by CMIA（ Chemiluminescent Microparticle Immunoassay ）~. The accepted protective serum anti-HBs level was ≥10 mIU/ml" (NCT02991599)
Timeframe: Month 12

InterventionParticipants (Count of Participants)
IM 20μg Group41
IM 60μg Group43

Number and Rate of Participants With Anti-HBs Seroconversion at Month 18

"The measurements of anti-HBs antibodies were determined quantitatively by CMIA（ Chemiluminescent Microparticle Immunoassay ）~. The accepted protective serum anti-HBs level was ≥10 mIU/ml" (NCT02991599)
Timeframe: Month 18

InterventionParticipants (Count of Participants)
IM 20μg Group29
IM 60μg Group29

Number and Rate of Participants With Anti-HBs Seroconversion at Month 30

"The measurements of anti-HBs antibodies were determined quantitatively by CMIA（ Chemiluminescent Microparticle Immunoassay ）~. The accepted protective serum anti-HBs level was ≥10 mIU/ml" (NCT02991599)
Timeframe: Month 30

InterventionParticipants (Count of Participants)
IM 20μg Group20
IM 60μg Group25

Number and Rate of Participants With Anti-HBs Seroconversion at Month 42

"The measurements of anti-HBs antibodies were determined quantitatively by CMIA（ Chemiluminescent Microparticle Immunoassay ）~. The accepted protective serum anti-HBs level was ≥10 mIU/ml" (NCT02991599)
Timeframe: Month 42

InterventionParticipants (Count of Participants)
IM 20μg Group14
IM 60μg Group20

Number and Rate of Participants With Anti-HBs Seroconversion at Month 7

"The measurements of anti-HBs antibodies were determined quantitatively by CMIA（ Chemiluminescent Microparticle Immunoassay ）~. The accepted protective serum anti-HBs level was ≥10 mIU/ml." (NCT02991599)
Timeframe: Month 7

InterventionParticipants (Count of Participants)
IM 20μg Group59
IM 60μg Group62

Occurrence of Adverse Events After Vaccination

Occurrence of adverse reactions within 28 days after vaccination with the hepatitis B vaccine (NCT02991599)
Timeframe: Within 28 days after the vaccination, at Month 0, 1, and 6

InterventionParticipants (Count of Participants)
IM 20μg Group2
IM 60μg Group3

Occurrence of Adverse Events After Vaccination

Occurrence of adverse reactions within 7 days after vaccination with the hepatitis B vaccine (NCT02991599)
Timeframe: Within 7 days after the vaccination, at Month 0, 1, and 6

InterventionParticipants (Count of Participants)
IM 20μg Group7
IM 60μg Group8

Number of Participants Linked to Care

"This will be assessed based on the number of participants who attend an appointment at the Viral Hepatitis Clinic within 60 days of enrolling in the study. A participant is considered linked to care if he/she attends an appointment at the clinic. A participant is considered not linked to care if he/she does not attend an appointment at the clinic. Whether a participant linked to care will be determined by looking at the medical record, where all attended appointments are documented. If no attended appointment is documented, this will be considered non-attendance/not linked to care." (NCT02707991)
Timeframe: 60 days

InterventionParticipants (Count of Participants)
Enhanced Usual Care8
Nurse Case Management16

Time to Hepatitis C Treatment Initiation

Number of days from study enrollment to receipt of the first dose of hepatitis C treatment (NCT02707991)
Timeframe: 6 months

Interventiondays (Mean)
Enhanced Usual Care103
Nurse Case Management79.3

Reviews

2 reviews available for methadone and Hepatitis B

ArticleYear
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
[Pregnancy and drug abuse: current situation and therapeutic strategies].
    Annales de medecine interne, 2000, Volume: 151 Suppl B

    Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adult; Female; Fetal Growth Retardation; Hepatit

2000

Trials

9 trials available for methadone and Hepatitis B

ArticleYear
Immunogenicity, safety, and compliance of high- and standard-strength four-dose hepatitis B vaccination regimens in patients receiving methadone maintenance therapy in China: a randomized, parallel-arm controlled trial.
    Expert review of vaccines, 2021, Volume: 20, Issue:12

    Topics: Hepatitis B; Hepatitis B Antibodies; Hepatitis B Vaccines; Humans; Methadone; Vaccination

2021
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
Long-term durability of immunogenicity induced by standard and triple-dose hepatitis B vaccine in patients receiving methadone maintenance treatment.
    Expert review of vaccines, 2020, Volume: 19, Issue:9

    Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Hepatitis B

2020
Immunogenicity and safety of a high-dose hepatitis B vaccine among patients receiving methadone maintenance treatment: A randomized, double-blinded, parallel-controlled trial.
    Vaccine, 2017, 04-25, Volume: 35, Issue:18

    Topics: Adolescent; Adult; Aged; Analgesics, Opioid; Double-Blind Method; Female; Hepatitis B; Hepatitis B A

2017
A randomized trial of a hepatitis care coordination model in methadone maintenance treatment.
    American journal of public health, 2013, Volume: 103, Issue:10

    Topics: Adult; Confidence Intervals; Female; Hepatitis A; Hepatitis B; Humans; Male; Methadone; Middle Aged;

2013
Education and counseling in the methadone treatment setting improves knowledge of viral hepatitis.
    Journal of substance abuse treatment, 2014, Volume: 46, Issue:4

    Topics: Adult; Counseling; Female; Follow-Up Studies; Health Knowledge, Attitudes, Practice; Hepatitis A; He

2014
Viral hepatitis among drug users in methadone maintenance: associated factors, vaccination outcomes, and interventions.
    Journal of addictive diseases, 2014, Volume: 33, Issue:4

    Topics: Adult; Aged; Female; Hepatitis A; Hepatitis B; Hepatitis C; Humans; Male; Methadone; Middle Aged; Ne

2014
Predictors of hepatitis knowledge improvement among methadone maintained clients enrolled in a hepatitis intervention program.
    Journal of community health, 2010, Volume: 35, Issue:4

    Topics: Female; Follow-Up Studies; Health Knowledge, Attitudes, Practice; Health Promotion; Hepatitis A; Hep

2010
Controlled trial of prescribed heroin in the treatment of opioid addiction.
    Journal of substance abuse treatment, 2006, Volume: 31, Issue:2

    Topics: Adult; Counseling; Drug Administration Schedule; Drug Prescriptions; Female; Health Status; Hepatiti

2006

Other Studies

33 other studies available for methadone and Hepatitis B

ArticleYear
A 35-year follow-up study of patients admitted to methadone treatment between 1982-1984 in Asturias, Spain.
    Adicciones, 2023, Sep-01, Volume: 35, Issue:3

    Topics: Female; Follow-Up Studies; Hepatitis B; Hepatitis C; Heroin; Heroin Dependence; HIV Seropositivity;

2023
Seroprevalence of hepatitis B virus infection, anti-HCV antibodies and HIV and knowledge among people who use drugs attending methadone therapy clinic in Tanzania; a cross-sectional study.
    BMC infectious diseases, 2021, Jul-21, Volume: 21, Issue:1

    Topics: Adolescent; Adult; Ambulatory Care Facilities; Cross-Sectional Studies; Drug Users; Female; Health K

2021
High prevalence but low awareness of hepatitis C virus infection among heroin users who received methadone maintenance therapy in Taiwan.
    Addictive behaviors, 2013, Volume: 38, Issue:4

    Topics: Adult; Analgesics, Opioid; Criminals; Female; Health Knowledge, Attitudes, Practice; Hepatitis B; He

2013
Evaluation of state opioid substitution treatment program in Georgia.
    Georgian medical news, 2014, Issue:229

    Topics: Adult; Aged; Alcoholism; Buprenorphine; Female; Georgia (Republic); Government Programs; Hepatitis B

2014
Hepatitis B and C prevalence among heroin addicts in methadone maintenance treatment (MMT) and not in MMT in Pereira, Colombia.
    Journal of infection in developing countries, 2014, Sep-12, Volume: 8, Issue:9

    Topics: Adult; Colombia; Female; Hepatitis B; Hepatitis C; Heroin Dependence; Humans; Male; Methadone; Preva

2014
Effectiveness of Methadone Maintenance Therapy and Improvement in Quality of Life Following a Decade of Implementation.
    Journal of substance abuse treatment, 2016, Volume: 69

    Topics: Adult; Follow-Up Studies; Hepatitis B; Heroin Dependence; HIV Infections; Humans; Interpersonal Rela

2016
A 25-year follow-up of patients admitted to methadone treatment for the first time: mortality and gender differences.
    Addictive behaviors, 2011, Volume: 36, Issue:12

    Topics: Adult; Aged, 80 and over; Female; Follow-Up Studies; Hepatitis B; Hepatitis C; Heroin Dependence; HI

2011
Hepatitis B virus and hepatitis C virus services offered by substance abuse treatment programs in the United States.
    Journal of substance abuse treatment, 2012, Volume: 42, Issue:4

    Topics: Cross-Sectional Studies; Guidelines as Topic; Health Services; Health Services Accessibility; Hepati

2012
Survey of methadone-drug interactions among patients of methadone maintenance treatment program in Taiwan.
    Substance abuse treatment, prevention, and policy, 2012, Mar-20, Volume: 7

    Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Arrhythmias, Cardiac; Drug Interactions; Female;

2012
[Prevalence of serological markers of viral hepatitis B and hepatitis C in drug-dependent individuals treated at the Drop Methadone Center in Prague].
    Casopis lekaru ceskych, 2003, Volume: 142, Issue:4

    Topics: Adult; Czech Republic; Female; Hepatitis A; Hepatitis B; Hepatitis C; Humans; Male; Methadone; Middl

2003
Prevalence of HIV, hepatitis B, C and G virus infections among injecting drug users on methadone maintenance treatment in Maribor.
    Wiener klinische Wochenschrift, 2004, Volume: 116 Suppl 2

    Topics: Adult; Age Factors; Cross-Sectional Studies; Female; Flaviviridae Infections; GB virus C; Hepatitis

2004
Methadone maintenance treatment in the Swiss Canton of Vaud: demographic and clinical data on 1,782 ambulatory patients.
    European addiction research, 2005, Volume: 11, Issue:2

    Topics: Adult; Ambulatory Care; Catchment Area, Health; Demography; Female; Hepatitis B; Hepatitis B Vaccine

2005
Linkage with methadone treatment upon release from incarceration: a promising opportunity.
    Journal of addictive diseases, 2005, Volume: 24, Issue:3

    Topics: Crime; Health Services Needs and Demand; Hepatitis B; Hepatitis C; HIV Infections; Humans; Long-Term

2005
HIV sexual risk behaviors among injection drug users in Shanghai.
    Drug and alcohol dependence, 2006, Volume: 82 Suppl 1

    Topics: Adult; Catchment Area, Health; China; Cross-Sectional Studies; Demography; Female; Hepatitis B; Hepa

2006
Management of hepatitis C among drug users attending general practice in Ireland: baseline data from the Dublin area hepatitis C in general practice initiative.
    The European journal of general practice, 2007, Volume: 13, Issue:1

    Topics: Adult; Aged; Family Practice; Female; Hepatitis B; Hepatitis C; HIV Infections; Humans; Illicit Drug

2007
Methadone maintenance treatment (MMT) in general practice or in specialized centers: profile of patients in the Swiss Canton of Vaud.
    The American journal of drug and alcohol abuse, 2007, Volume: 33, Issue:5

    Topics: Adult; AIDS Serodiagnosis; Antipsychotic Agents; Cocaine-Related Disorders; Cross-Sectional Studies;

2007
Alcohol use in youthful methadone-maintained former heroin addicts: liver impairment and treatment outcome.
    Alcoholism, clinical and experimental research, 1983,Summer, Volume: 7, Issue:3

    Topics: Adolescent; Adult; Alcohol Drinking; Alcoholism; Female; Hepatitis B; Heroin Dependence; Humans; Liv

1983
Immune response to hepatitis B vaccine in drug addicts.
    The Journal of infection, 1983, Volume: 7 Suppl 1

    Topics: Hepatitis B; Hepatitis B Antibodies; Hepatitis B virus; Humans; Inactivation, Metabolic; Medical Sta

1983
Medical disorders in a cohort of New York city drug abusers: much more than HIV disease.
    Journal of addictive diseases, 1993, Volume: 12, Issue:4

    Topics: Adult; Aged; Blood Chemical Analysis; Female; Health Status; Hepatitis B; HIV Seropositivity; Hospit

1993
A longitudinal study on the incidence and transmission patterns of HIV, HBV and HCV infection among drug users in Amsterdam.
    European journal of epidemiology, 1993, Volume: 9, Issue:3

    Topics: Adult; Comorbidity; Condoms; Female; Germany; Hepatitis B; Hepatitis C; HIV Infections; Homosexualit

1993
Addiction treatment: promoting a medical approach to substance use.
    Journal of urban health : bulletin of the New York Academy of Medicine, 1998, Volume: 75, Issue:3

    Topics: Blood-Borne Pathogens; Delivery of Health Care, Integrated; Financial Support; Health Promotion; Hea

1998
Prevalence and incidence rate of HIV, hepatitis B and C among drug users on methadone maintenance treatment in Geneva between 1988 and 1995.
    AIDS (London, England), 1998, Oct-22, Volume: 12, Issue:15

    Topics: Cohort Studies; Female; Hepatitis B; Hepatitis C; HIV Infections; Humans; Incidence; Male; Methadone

1998
Methadone-maintained former heroin addicts, including those who are anti-HIV-1 seropositive, comply with and respond to hepatitis B vaccination.
    Addiction (Abingdon, England), 1999, Volume: 94, Issue:4

    Topics: Adult; Female; Hepatitis B; Hepatitis B Vaccines; Heroin Dependence; HIV Seropositivity; Humans; Inj

1999
[Axillary plexus catheter block in accidental intra-arterial levomethadone HCl injection in an HIV-positive, hepatitis B and C active drug dependent patient].
    Handchirurgie, Mikrochirurgie, plastische Chirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Handchirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Mikrochirurgie der Peripheren Nerven und Gefasse : Organ der V..., 2000, Volume: 32, Issue:3

    Topics: Adult; Amides; Anesthetics, Local; Arm; Axillary Artery; Blood Flow Velocity; Brachial Plexus; Cathe

2000
Methadone treatment and HIV and hepatitis B and C risk reduction among injectors in the Seattle area.
    Journal of urban health : bulletin of the New York Academy of Medicine, 2000, Volume: 77, Issue:3

    Topics: Adult; Cohort Studies; Female; Hepatitis B; Hepatitis C; HIV Infections; Humans; Incidence; Male; Me

2000
Hepatitis C, B, D, and A: contrasting features and liver function abnormalities in heroin addicts.
    Journal of addictive diseases, 2001, Volume: 20, Issue:1

    Topics: Carrier State; Hepatitis A; Hepatitis B; Hepatitis C; Hepatitis D; Heroin Dependence; Humans; Liver

2001
Prevalence of hepatitis B and C infection in a methadone clinic population: implications for hepatitis B vaccination.
    The New Zealand medical journal, 2001, Jul-27, Volume: 114, Issue:1136

    Topics: Adult; Comorbidity; Cross-Sectional Studies; Feasibility Studies; Female; Hepatitis B; Hepatitis B V

2001
HIV and hepatitis virus infections among injecting drug users in a medically controlled heroin prescription programme.
    European journal of public health, 2001, Volume: 11, Issue:4

    Topics: Adult; Drug Prescriptions; Female; Health Policy; Hepatitis B; Hepatitis C; Heroin; HIV Infections;

2001
Dental implications of narcotic addiction.
    Australian dental journal, 1978, Volume: 23, Issue:4

    Topics: Dental Caries; Diet; Endocarditis; Hepatitis B; Humans; Methadone; Narcotics; Periodontal Diseases;

1978
Viral hepatitis with intracytoplasmic cholestasis and cholesterol crystals in a drug addict.
    The Journal of pathology, 1975, Volume: 116, Issue:1

    Topics: Acute Disease; Adolescent; Cholestasis; Cholesterol; Crystallization; Cytoplasm; Diazepam; Female; H

1975
Incidence of hepatitis C, hepatitis B and HIV infections among drug users in a methadone-maintenance programme.
    AIDS (London, England), 1992, Volume: 6, Issue:4

    Topics: Hepatitis B; Hepatitis C; HIV Infections; Humans; Incidence; Methadone; Substance Abuse, Intravenous

1992
Race and risk of hepatitis in narcotic addicts.
    The American journal of digestive diseases, 1973, Volume: 18, Issue:6

    Topics: Adult; Age Factors; Aspartate Aminotransferases; Black People; Female; Hepatitis B; Hepatitis B Anti

1973
The New York City Methadone Maintenance Treatment Program after two years - an overview.
    Proceedings. National Conference on Methadone Treatment, 1973, Volume: 1

    Topics: Adolescent; Community Health Services; Crime; Female; Hepatitis B; Heroin Dependence; Humans; Methad

1973